LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Fosun Pharmaceutical and Shanghai drugs open innovation model
Shanghai Fosun Pharmaceutical (SFP) has announced that it will cooperate with the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences to jointly develop three targets for anti-tumor innovative drugs. This cooperation is different from the previous “research alliances”, or Clinical Research Organization (CRO) model, as both sides will not only share the risks involved, but also the results and benefits of the cooperation. They will also jointly own the patents of the innovative drugs.

In recent years, SFP has focused on the development of the pharmaceutical business, continuing to increase the intensity of its research and innovation. It completed the layout of the new research and development system, forming a unique “4 +1” research and development platform.

The platform optimizes drug design and lead compounds, together with rapid synthesis, producing a class of 6 drugs (one upcoming in a clinical report) from development of the project within three years. In this partnership, Fosun Pharma will allow full play of the unique advantages of the complex record platform to accelerate the implementation of innovative strategies. The partners will complement each other, share resources, to achieve a true sense of new drug research alliances in order to achieve a win-win situation.

The Fosun Pharma Chairman Chen Chi-yu said, “The cooperation benefited from the paradigm shift in the foundation continues to strengthen the endogenous R & D strength of the company. Shanghai Institute of Materia Medica, Chinese Academy of Sciences truly brought together a top team of scientists in drug research. The private pharmaceutical innovation force, coupled with the cooperation of the innovative ability of the national team, will lead Fosun Pharma's innovative drugs to comprehensively enhance the 5 protein kinases and accelerate Fosun Pharmaceutical's anti-tumor drug project progress, adding more ‘blockbuster’ product lines to its reserve.”

James Ding, academician and Director of the Shanghai Institute of Materia Medica, said: "Relying on technology independent innovation of China's bio-pharmaceutical industry into such an important strategic transition period, and changing the growth mode of the cooperation with Fosun Pharma, is to take the integrated innovation strategy and cooperation's international strategy to create a in-win outcome. Through sincere cooperation to develop good medicine the Chinese people can afford to eat innovative drugs in China and as soon as possible bring it to the international community to better benefit the people, we believe Fosun Pharmaceutical's industry resources and new drug research and development capabilities, together with cooperation of the Shanghai Institute of Materia Medica, the complementary advantages and powerful alliances, will surely contribute to the three-step plan of China's bio-pharmaceutical development.


Click here for the complete issue.

news Runners' High, Happy Feet — If you're Happy, and you know it 'Clap' your Feet
news Snapshot of Stem Cell Expression using Single-cell RNA Sequencing
news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy